The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 34; no. 9; pp. 2059 - 2065
• Main Authors: Chen, M., Chen, W., Liu, P., Yan, K., Lv, C., Zhang, M., Lu, Y., Qin, Q., Kuang, Y., Zhu, W., Chen, X.
• Format: Journal Article
• Language: English
• Published: England 01-09-2020
• Subjects: Adult; Aged; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - genetics; Asian Continental Ancestry Group - genetics; China; Female; Humans; Male; Methotrexate - therapeutic use; Middle Aged; Psoriasis - drug therapy; Psoriasis - genetics; Treatment Outcome; Young Adult; China
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.16440

Background
Methotrexate (MTX) is the first‐line treatment for psoriasis in China. The metabolic processes of MTX include various proteins and genes. Previous studies have shown that gene polymorphisms had significant impacts on the efficacy of MTX. However, the influence of gene polymorphisms has not been reported in the Chinese psoriatic patients.
Objective
The aim of this study was to verify the impacts of candidate genes polymorphisms on the effectiveness of MTX in a Chinese psoriatic population.
Methods
In this study, we enrolled 259 psoriasis patients from two clinical centres. Each of them received MTX treatment at 7.5–15 mg/week for at least 8 weeks. Patients were stratified as responders and non‐responders according to whether the Psoriasis Area and Severity Index score declined more than 75% (PASI75). According to previous reports, 16 single nucleotide polymorphisms (SNPs) were selected and genotyped for each patient using the Sequenom platform. Fisher’s exact test, the chi‐square test, Mann–Whitney tests and ANOVA analyses were used for statistical analysis.
Results
Among 259 patients, there were 182 males and 77 females, 63 patients with psoriatic arthritis and 196 patients without arthritis phenotype, and the age of all patients ranged from 19 to 70 years (49.7 ± 13.6). The baseline PASI value of patients was 13.8 ± 8.5, and 33.2% of patients achieved a PASI75 response after MTX treatment. Patients carrying the ATP‐binding cassette subfamily B member 1 gene (ABCB1) rs1045642 TT genotype were associated with more severe psoriasis skin lesion (P = 0.032). Furthermore, the ABCB1 rs1045642 TT genotype was found to be more frequent in non‐responders (P = 0.017), especially in moderate‐to‐severe patients (P = 0.002) and patients without psoriatic arthritis (P = 0.026) after MTX treatment.
Conclusion
We have demonstrated for the first time that polymorphism of the ABCB1 rs1045642 TT genotype is predictive of a worse clinical response of skin lesions to MTX therapy in a Chinese psoriatic population.